Merck’s Experimental Cholesterol Pill Shows Promising Results in Phase 3 Trial

An investigational daily pill developed by Merck, designed to lower LDL cholesterol, demonstrated significant reductions in a late-stage clinical trial, potentially offering a new treatment option for patients who don’t achieve sufficient cholesterol control with statins alone.

The Phase 3 CORALreef Lipids trial, results of which were released today, showed that the oral medication, known as enlicitide decanoate, significantly reduced LDL-C levels. The trial involved patients already taking statins, the current standard of care for managing cholesterol. Lowering LDL cholesterol is crucial in reducing the risk of heart attack and stroke, major causes of death worldwide.

The results indicate the pill’s effectiveness is comparable to that of injectable PCSK9 inhibitors, currently the most potent cholesterol-lowering drugs available, but offers the convenience of a daily pill. Researchers noted the findings could broaden access to advanced cholesterol management for a wider range of patients. For more information on managing cholesterol, resources are available from the American Heart Association.

Merck is now preparing to submit the data to regulatory authorities for potential approval. Further details on cardiovascular outcomes will be closely watched as the company continues its research into cardiovascular health. Officials stated they are encouraged by the results and look forward to discussing the findings with health regulators.